

# Hisato Kawakami

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3966288/publications.pdf>

Version: 2024-02-01

109  
papers

3,488  
citations

201385

27  
h-index

155451

55  
g-index

111  
all docs

111  
docs citations

111  
times ranked

5012  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2419-2430.	13.9	681
2	Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 30.	1.3	309
3	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	5.1	234
4	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	15.2	209
5	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 529-536.	1.2	128
6	Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection. <i>PLoS ONE</i> , 2014, 9, e101902.	1.1	106
7	Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 651-658.	2.4	99
8	Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 378-389.	1.5	99
9	Targeting MET Amplification as a New Oncogenic Driver. <i>Cancers</i> , 2014, 6, 1540-1552.	1.7	96
10	<i>HER2</i> amplification as a potential therapeutic target in gastric cancer. <i>Oncotarget</i> , 2013, 4, 9-17.	0.8	82
11	An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. <i>Oncogene</i> , 2019, 38, 1398-1409.	2.6	69
12	[Fam] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification. <i>International Journal of Cancer</i> , 2019, 145, 3414-3424.	2.3	62
13	The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. <i>Oncotarget</i> , 2014, 5, 11847-11856.	0.8	61
14	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 347-354.	1.2	57
15	Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. <i>Cancer Medicine</i> , 2019, 8, 1258-1268.	1.3	54
16	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. <i>Cancers</i> , 2020, 12, 400.	1.7	50
17	Implications of mismatch repair-deficient status on management of early stage colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 676-84.	0.6	49
18	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. <i>European Journal of Cancer</i> , 2020, 129, 97-106.	1.3	48

#	ARTICLE	IF	CITATIONS
19	Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2021, 26, e588-e596.	1.9	48
20	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4000-4000.	0.8	48
21	The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. <i>Journal of Biological Chemistry</i> , 2015, 290, 23838-23849.	1.6	46
22	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388.	3.9	43
23	KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non-“Small Cell Lung Cancer Induced By RAS- and Non-“RAS-Mediated Cell Signaling Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 5697-5707.	3.2	42
24	<i>MET</i> -targeted therapy for gastric cancer: the importance of a biomarker-based strategy. <i>Gastric Cancer</i> , 2016, 19, 687-695.	2.7	37
25	Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. <i>British Journal of Cancer</i> , 2021, 124, 914-924.	2.9	37
26	Mutant <i>BRAF</i> Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 3015-3027.	1.9	36
27	HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 390-403.	3.2	34
28	Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-“small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 52-60.	1.7	31
29	Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). <i>Esophagus</i> , 2021, 18, 90-99.	1.0	30
30	Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 1-25.	1.4	29
31	Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma. <i>Cancer Medicine</i> , 2013, 2, 933-941.	1.3	27
32	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
33	HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 267-274.	0.8	25
34	Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. <i>Molecular Cancer Research</i> , 2015, 13, 659-669.	1.5	22
35	T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-“Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2563-2571.	1.9	19
36	Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. <i>Oncotarget</i> , 2016, 7, 84860-84871.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. <i>Investigational New Drugs</i> , 2018, 36, 726-731.	1.2	17
38	Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e239-e241.	0.5	17
39	Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).. <i>Journal of Clinical Oncology</i> , 2021, 39, 161-161.	0.8	17
40	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. <i>Molecular Oncology</i> , 2022, 16, 1493-1507.	2.1	17
41	Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08). <i>Gastric Cancer</i> , 2022, 25, 235-244.	2.7	17
42	Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. <i>European Journal of Cancer</i> , 2013, 49, 3003-3009.	1.3	16
43	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3505-3505.	0.8	16
44	Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGS1105, HERBIS-4A Trial. <i>Oncologist</i> , 2018, 23, 1411-e147.	1.9	15
45	Human Epidermal Growth Factor Eyedrops for Cetuximab-Related Filamentary Keratitis. <i>Journal of Clinical Oncology</i> , 2011, 29, e678-e679.	0.8	14
46	Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. <i>Cancer Science</i> , 2013, 104, 98-104.	1.7	14
47	Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGS1602. <i>Oncologist</i> , 2021, 26, 17-e47.	1.9	13
48	A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. <i>Scientific Reports</i> , 2019, 9, 11340.	1.6	12
49	Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. <i>Oncogenesis</i> , 2019, 8, 54.	2.1	12
50	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT). <i>Journal of Clinical Oncology</i> , 2021, 39, 1077-1084.	1.7	10
51	Folate receptor 1 increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAB-02 in gastric cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e454.	1.7	11
52	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer. <i>Investigational New Drugs</i> , 2014, 32, 946-954.	1.2	10
53	Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. <i>Oncologist</i> , 2019, 24, 163.	1.9	10
54	A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical Stage III Gastric Cancer (OGS1601). <i>Oncologist</i> , 2020, 25, 119.	1.9	10

#	ARTICLE	IF	CITATIONS
55	Phase III study of pembrolizumab combined with S-1 oxaliplatin or S-1 cisplatin as first-line chemotherapy for gastric cancer. <i>Cancer Science</i> , 2022, 113, 2814-2827.	1.7	10
56	Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 1921-1929.	0.6	9
57	Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S-1 chemotherapy after gastrectomy: A multicenter, open-label, single-arm, prospective phase II study (OGSG1108). <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 776-784.	1.2	9
58	Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. <i>Oncotarget</i> , 2017, 8, 80286-80294.	0.8	9
59	FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2021, 112, 314-322.	1.7	8
60	Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. <i>Esophagus</i> , 2022, 19, 137-145.	1.0	8
61	DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer. <i>Future Oncology</i> , 2019, 15, 2441-2447.	1.1	7
62	Comparison of S-1 cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1635-1643.	1.0	7
63	Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3). <i>Gastric Cancer</i> , 2021, 24, 428-434.	2.7	7
64	Serum lactate dehydrogenase is a predictive biomarker in patients with oropharyngeal cancer undergoing radiotherapy: Retrospective study on predictive factors. <i>Head and Neck</i> , 2021, 43, 3132-3141.	0.9	7
65	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01). <i>Journal of Clinical Oncology</i> , 2020, 38, 4513-4513.	0.8	7
66	REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. <i>Future Oncology</i> , 2021, 17, 869-875.	1.1	6
67	A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). <i>International Journal of Clinical Oncology</i> , 2020, 25, 2035-2043.	1.0	5
68	Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802). <i>International Journal of Clinical Oncology</i> , 2020, 25, 1291-1298.	1.0	5
69	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-242.	0.8	5
70	Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 279-285.	1.1	4
71	Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. <i>European Journal of Cancer</i> , 2021, 154, 307-315.	1.3	4
72	Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR). <i>Journal of Clinical Oncology</i> , 2018, 36, 670-670.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Two-step Intensity-modulated Radiation Therapy for Oropharyngeal Cancer: Initial Clinical Experience and Validation of Clinical Staging. <i>Anticancer Research</i> , 2018, 38, 979-986.	0.5	4
74	Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 322-322.	0.8	3
75	Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, v231-v232.	0.6	2
76	Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 4050.	1.0	2
77	The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19082-e19082.	0.8	2
78	Pharmacokinetics (PK) and Safety of Teseaxel, a Novel Oral Taxane, in Japanese Patients (PTS) with Advanced Solid Tumors. <i>Annals of Oncology</i> , 2012, 23, ix167.	0.6	1
79	A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood. <i>Case Reports in Oncology</i> , 2020, 13, 843-848.	0.3	1
80	Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1871-1880.	1.0	1
81	Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	0.8	1
82	Abstract 2937: MEK/ERK inhibitor GDC-0623 dephosphorylates and accumulates BIM that enables a synergistic apoptosis with the Bcl-xL antagonist, ABT-263, in mutantKRAScolorectal cancer cells. , 2015, , .		1
83	Abstract 2173: Targeting CDK1 and MEK/ERK overcome mutantBRAF-mediated apoptosis resistance in human colorectal cancer cells. , 2017, , .		1
84	Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 624-624.	0.8	1
85	Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15106-e15106.	0.8	1
86	Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.. <i>Journal of Clinical Oncology</i> , 2019, 37, 578-578.	0.8	1
87	OUP accepted manuscript. <i>Oncologist</i> , 2022, 27, 251-e304.	1.9	1
88	Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus Sâ€™â€™ therapy. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
89	Heregulin as a Biomarker for Anti-Her3 Antibody Patritumab Combined with Erlotinib in Non-Small Cell Lung Cancer. <i>Annals of Oncology</i> , 2014, 25, v73.	0.6	0
90	Clinical Benefit of Continued Therapy with Crizotinib Beyond Initial Disease Progression in Advanced Alk Positive Nscl. <i>Annals of Oncology</i> , 2014, 25, v70.	0.6	0



#	ARTICLE	IF	CITATIONS
91	49 Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Bcl-xL Antagonism and Induction of Pro-Apoptotic BH3-Only Proteins in Colorectal Carcinoma Cells. <i>Gastroenterology</i> , 2015, 148, S-15.	0.6	0
92	Sa1808 Mutant BRAF (V600E) Phosphorylates MCL-1 to Increase Stability/Expression That Confers Apoptosis Resistance in Colorectal Cancer Cells. <i>Gastroenterology</i> , 2016, 150, S372.	0.6	0
93	A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601).. <i>Journal of Clinical Oncology</i> , 2021, 39, 203-203.	0.8	0
94	Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer: OGSG 1602, survival update data.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3558-3558.	0.8	0
95	Randomized phase II study comparing docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma who are refractory to fluoropyrimidine and platinum-based chemotherapy: OGSG1201.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4037-4037.	0.8	0
96	Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer.. , 2013, , .		0
97	Phase I dose finding study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, alone or in combination with paclitaxel in Japanese patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e13501-e13501.	0.8	0
98	Abstract 1844: Novel HER3 neutralizing antibody, patritumab abrogates cetuximab resistance mediated by a heregulin-autocrine loop in colorectal cancer. , 2014, , .		0
99	Abstract 2939: Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo. , 2016, , .		0
100	Abstract 2115: MEK/ERK and MCL-1 inhibition synergistically reverse apoptosis resistance in colon cancer cells with BRAF(V600E)-mediated MCL-1-upregulation. , 2016, , .		0
101	Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 603-603.	0.8	0
102	Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102.	0.8	0
103	The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS885-TPS885.	0.8	0
104	Abstract 2336: Targeting CDK1 and MEK/ERK overcomes apoptosis resistance in BRAFV600E human colorectal cancer cells. , 2018, , .		0
105	REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progressive disease of nivolumab (NIV) therapy for metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS178-TPS178.	0.8	0
106	A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-144.	0.8	0
107	Abstract 1668: A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. , 2019, , .		0
108	Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4071-4071.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer: A Phase II Study (OGSG 1107). <i>Gastrointestinal Tumors</i> , 2022, 9, 27-36.	0.3	0